ACT 178882

Drug Profile

ACT 178882

Alternative Names: ACT-178882; MK-1597

Latest Information Update: 01 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Actelion Pharmaceuticals; Merck & Co
  • Developer Actelion Pharmaceuticals
  • Class Amides; Antihypertensives; Piperidines; Pyrimidines
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 05 Feb 2013 Phase-I clinical trials in Hypertension in Switzerland (PO)
  • 05 Feb 2013 Drug interactions & adverse events data from a phase I trial in Healthy volunteers released by Actelion Pharmaceuticals
  • 19 Jul 2012 ACT 178882 is available for licensing as of 19 Jul 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top